BioAtla, Inc. (BCAB)
Market Cap | 188.59M |
Revenue (ttm) | n/a |
Net Income (ttm) | -102.33M |
Shares Out | 46.11M |
EPS (ttm) | -2.74 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 332,033 |
Open | 4.15 |
Previous Close | 4.14 |
Day's Range | 4.02 - 4.31 |
52-Week Range | 2.01 - 12.15 |
Beta | 0.63 |
Analysts | Buy |
Price Target | 26.67 (+552.08%) |
Earnings Date | Mar 7, 2023 |
About BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen... [Read more]
Financial Performance
In 2021, BioAtla's revenue was $250,000, a decrease of -41.72% compared to the previous year's $429,000. Losses were -$95.40 million, 166.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for BCAB stock is "Buy." The 12-month stock price forecast is $26.67, which is an increase of 552.08% from the latest price.
News

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

Viatris Announces Appointments of Scott A. Smith and Elisha W.
Directors Neil Dimick and Ian Read Retire PITTSBURGH , Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W.

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect?
The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

BioAtla to Participate in the Jefferies London Healthcare Conference
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BioAtla Announces $65 Million Underwritten Offering of its Common Stock
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)
Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 Undifferentiated Pleomorphic Sarc...

BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

BioAtla to Participate in the 2022 BTIG Biotechnology Conference
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

BioAtla to Participate in 2022 Jefferies Global Healthcare Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress
– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and...

BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
SAN DIEGO, March 1, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu...

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors
SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu...

BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS
SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today ann...

BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update
SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu...

BioAtla Announces Private Placement of 2.7 Million Shares
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therape...

BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update
SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu...